Used in targeted cancer therapy, particularly for non-small cell lung cancer (NSCLC) with KRAS G12C mutation. It selectively binds to the inactive form of the mutant KRAS protein, trapping it in an inactive state and blocking downstream signaling pathways involved in cell proliferation and survival. This inhibition leads to reduced tumor growth and is especially effective in tumors driven by this specific genetic alteration. Currently utilized in clinical settings for patients with advanced or metastatic disease who have limited treatment options.